Results 81 to 90 of about 13,617 (225)
Allergology International, 2018 Background: Omalizumab, a humanized anti-IgE monoclonal antibody, proved efficacious and well tolerated in patients with chronic spontaneous urticaria (CSU) refractory to H1 antihistamines (H1AH) in the POLARIS study (NCT02329223), a randomized, double ...
Michihiro Hide +10 more
doaj +1 more source
A Case for Anti-IgE Vaccination. [PDF]
AllergyABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Engeroff P +3 more
europepmc +2 more sources
, 2012 Ayad K Ali, Abraham G HartzemaDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USABackground: Omalizumab is a monoclonal antibody, indicated for the treatment of severe allergic asthma.
Ali AK, Hartzema AG
core
Dermatologic uses of omalizumab
, 2017 Purpose: Omalizumab is a recombinant humanized monoclonal antibody that inhibits the binding of immunoglobulin E (IgE) to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils.
P. Régine Mydlarski, Justin C. Chia
core +1 more source
Allergy, EarlyView.Dupilumab significantly improved nasal polyp score, nasal congestion, olfaction, total symptom score, and disease‐specific quality of life in Chinese patients with uncontrolled CRSwNP. Incidence of treatment‐emergent adverse events was similar between dupilumab and placebo.
Mu Xian +18 more
wiley +1 more source
Risk Management and Healthcare Policy, 2020 Giorgio Walter Canonica, 1 Giorgio Lorenzo Colombo, 2, 3 Paola Rogliani, 4 Pierachille Santus, 5 Claudia Pitotti, 6 Sergio Di Matteo, 3 Chiara Martinotti, 3 Giacomo Matteo Bruno 3 1Asthma & Allergy Clinic, Humanitas University, Milan, Italy; 2S.A.V.
Canonica GW +7 more
doaj
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. [PDF]
, 2020 Targeting of immunoglobulin E (IgE) represents an interesting approach for the treatment of allergic disorders. A high-affinity monoclonal anti-IgE antibody, ligelizumab, has recently been developed to overcome some of the limitations associated with the
Kleinboelting, Silke +19 more
core +1 more source
Clinical Features of Cellular Senescence Pathways in Severe Asthma
Allergy, EarlyView.In bronchial biopsies, SASP and p53 pathway enrichment scores are elevated in severe asthma versus non‐severe asthma and healthy controls. SASP enrichment is validated in the independent NOVA cohort. SASP enrichment is also elevated in nasal brushings of participants with nasal polyps, independently of asthma status.
Woo‐Jung Song +122 more
wiley +1 more source
Unpredicted adverse reaction to omalizumab
, 2011 Despite promising reports of the use of omalizumab as add-on therapy in patients with systemic mastocytosis and recurrent anaphylaxis during specific venom immunotherapy (VIT), unpredicted adverse effects may lead to therapy failure.
Jandus, P +5 more
core